Related party transactions	3 Months Ended
Mar. 31, 2020
Related party transactions
Related party transactions	12. Related-party transactions Historically, the Company has received consulting and management services from one of its investors. During the three months ended March 31, 2020 and 2019, there were no consulting and management services provided by this investor, and as of March 31, 2020, there were no amounts payable related to consulting and management service fees provided by this investor. Additionally, during the three months ended March 31, 2020, the Company received board and scientific advisory services from two of its former executives, Steven M. Paul, M.D., the Company’s former President and Chief Executive Officer, and Dinah Sah, Ph.D., the Company’s former Chief Scientific Officer. The total amount of fees paid to Dr. Paul for services provided during each of the three months ended March 31, 2019 and the three months ended March 31, 2020 was $0.1 million. The total amount of fees paid to Dr. Sah for services provided during the three months ended March 31, 2020 was $0.1 million. Under the collaboration agreement, the Company and Neurocrine have agreed to conduct research, development and commercialization of certain of the Company’s AAV gene therapy products (Note 8). Amounts due from Neurocrine are reflected as related party collaboration receivables. As of March 31, 2020, the Company had approximately $16.3 million in related party collaboration receivable associated with Neurocrine.

Related party transactions

3 Months Ended

Mar. 31, 2020

12. Related-party transactions

Historically, the Company has received consulting and management services from one of its investors. During the three months ended March 31, 2020 and 2019, there were no consulting and management services provided by this investor, and as of March 31, 2020, there were no amounts payable related to consulting and management service fees provided by this investor.

Additionally, during the three months ended March 31, 2020, the Company received board and scientific advisory services from two of its former executives, Steven M. Paul, M.D., the Company’s former President and Chief Executive Officer, and Dinah Sah, Ph.D., the Company’s former Chief Scientific Officer. The total amount of fees paid to Dr. Paul for services provided during each of the three months ended March 31, 2019 and the three months ended March 31, 2020 was $0.1 million. The total amount of fees paid to Dr. Sah for services provided during the three months ended March 31, 2020 was $0.1 million.

Under the collaboration agreement, the Company and Neurocrine have agreed to conduct research, development and commercialization of certain of the Company’s AAV gene therapy products (Note 8). Amounts due from Neurocrine are reflected as related party collaboration receivables. As of March 31, 2020, the Company had approximately $16.3 million in related party collaboration receivable associated with Neurocrine.